Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09THN
|
|||
| Former ID |
DNCL003501
|
|||
| Drug Name |
IMGN901
|
|||
| Synonyms |
Lorvotuzumab mertansine
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
ImmunoGen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neural cell adhesion molecule (NCAM) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Prion diseases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02420873) A Study of Lorvotuzumab Mertansine. U.S. National Institutes of Health. | |||
| REF 2 | Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. | |||
| REF 3 | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Nov;60(11):1860-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.